Predicted protein targets (top 2)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CCR1 | P32246 | 1/20 | 0.42 |
| ▸ | SLC6A3 | Q01959 | 2/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15478375 | 0.84 | CCR1 (0.50) | CCR1SLC6A3 | |
| SCHEMBL15478420 | 0.82 | CCR1 (0.37) | CCR1SLC6A3 | |
| SCHEMBL18895930 | 0.81 | CCR1 (0.43) | CCR1 | |
| SCHEMBL18633827 | 0.80 | CCR1 (0.39) | CCR1 | |
| SCHEMBL14420045 | 0.79 | CCR1 (0.40) | CCR1 | |
| SCHEMBL13824459 | 0.77 | CCR1 (0.40) | CCR1 | |
| SCHEMBL15478377 | 0.77 | CCR1 (0.39) | CCR1 | |
| SCHEMBL18896010 | 0.76 | CCR1 (0.39) | CCR1 | |
| SCHEMBL13824447 | 0.76 | CCR1 (0.39) | CCR1 | |
| SCHEMBL15478333 | 0.74 | DRD2 (0.40) | CCR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120046311-A1 | CHEMOKINE RECEPTOR ANTAGONISTS AND METHODS OF USE THEREOF | KYOWA HAKKO KOGYO CO., LTD. (JP) | 2012-02-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120046311-A1 | CHEMOKINE RECEPTOR ANTAGONISTS AND METHODS OF USE THEREOF | ACKR3, CCR2, CXCR2 | CCR1 9/4885SLC6A3 1141/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.